PULSAR Combined With Immunotherapy and Chemotherapy
NCT07291947
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Cholangiocarcinoma
Interventions
DRUG:
Iparomlimab and Tuvonralimab Injection (QL1706)
RADIATION:
PULSAR
Sponsor
Wang Xin